Member Info for draft

and half the price since interims and year end and the RNSs have been impressive and improving so this is a sale price in my opinion, should fire back up.

Total epic fail for me. I didnt realise they were not allowed to do betting in the US before today.

came over at pipehawk I did 150%.

cant find it

for the rise here, I was looking at this from 3.9p. No one has epxlained why this has risen?

What it means is Michael spencer is no fool and he has ADDED here. the only sign of the deramping c@nts here is that this share will do very well.

https://astanatimes.com/2018/03/kazakh-domestic-pharmaceutical-production-up-79-8-percent-in-2017/ Kazakh domestic pharmaceutical production up 79.8 percent in 2017 By Yerbolat Uatkhanov in Business on 2 March 2018 ASTANA � The Kazakh pharmaceutical industry increased production of the country�s most popular medications by 73.1 percent with production increasing 79.8 percent over 2016. Prices for pharmaceutical products in Kazakhstan have also increased 6.6 percent over the last 12 months.The production increases are an attempt by the Kazakh pharmaceutical industry to replace imports with domestic production. Among the high production areas were the Almaty region (52.8 percent of total domestic production), the South Kazakhstan region (18.3 percent) and Almaty (12.4 percent). Such large companies as AbdiIbahim GlobalPharm, Kelun-KazPharm, Dolce, Zerde-Fito, Chimpharm, Nobel Almaty Pharmaceutical Factory, Aurora, Cheminnova Alimor Kazpharm, Rapid-Alimor Pharm Industries, Dosfarm have plants in the regions, energyprom.kz reports. SANTO company, being a part of the international pharmaceutical group Polpharma (Poland), is implementing the largest investment project in the South Kazakhstan region to modernise the existing pharmaceutical production of Chimpharm in accordance with English Good Manufacturing Practice (GMP) international standards. The Polish investor will invest $37 million in the plant. The main objectives of the fourth stage of the investment programme of Polpharma international group for 2018-2022 are the development of the IT infrastructure, digitisation of the production process, the improvement and automation of the quality control and quality assurance system and the development of new medicines. The company is going to build a new laboratory as well as update existing infrastructure, equipment and logistics facilities. Over the 11 months of 2017, 14.3 percent of antibiotics sold in Kazakhstan were produced domestically. However, domestic production of other pharmaceuticals reached 53.1 percent of the total Kazakh market.

is Spencers worth today. and that's all you need to know

Michael Spencer in todays rich list 2018. there you go

https://www.pressandjournal.co.uk/fp/business/north-of-scotland/1464226/multi-millionaire-is-now-the-largest-single-shareholder-in-north-sea-oil-and-gas-firm-cluff-natural-resources/

he Rhum gas field in the North Sea, which supplies 5% of the UK's gas, is half-owned by the Iranian State Oil Company.BP, which owns the other half, is in the process of offloading its share to small North Sea specialist Serica, but that deal has not completed.BP does huge amounts of business in the US and will be desperately keen to avoid being seen as a business partner of the Iranian state. It's a good example of how sanctions against a state can have wide repercussions for the international business community. The chairman of Serica, Tony Craven-Walker, told the BBC he was still hopeful that the deal would close and that there would be no interruption to a major source of gas for UK families and businesses. However, one of the conditions of the deal closing is obtaining a licence to operate from the US Treasury Department, which is thrown into question with the imminent reintroduction of US sanctions against Iran. BP and Serica both said they had no plans to stop production in the short term. However, Serica conceded that it may have to change personnel and companies involved in the operation of the field to ensure there were no US individuals or entities involved.

Limitedaccess - I think you have missed the point that as Cluff have pointed this is a substantial new incoming game changing licence. Yes people were trading this from 1.75 to 2.15 etc. Anyone could spot that. You keep saying recycled old news etc but the macro climate has changed, MS has loaded up and hes not going to be taking 10% like you, we know full well OGA are about to announc etc and in TALKS with interested parties. Also there are not many undervalued companies left on AIM right now, this is one of them. So do you trade and leave for peanuts 10% which is what you are doing. Once this gets developed this will go flying and no its not the same old story anymore in my opinion. THE OGA licence round announcement is Overdue and could land anytime now. SO this is not in trading range, your not getting in lower sunshine!

Envoi AI now PACS compliant and strategic partner with UK company, baltantly going to take our IB and SC algorithms. https://www.envoyai.com/blog/envoyai-terarecon-and-insignia-partner-to-bring-artificial-intelligence-to-united-kingdom-customers. Cambridge, MA � May 10th, 2018 � EnvoyAI today announced a new integration with Insignia Medical Systems� InSight PACS to provide AI-enhanced imaging workflows to customers. For initial launch in the UK, this integration provides best-of-breed, curated AI content available on the EnvoyAI platform within the PACS environment at multiple integration points. These include AI results viewing directly within the PACS viewer, as well as within the already established Insignia integration with TeraRecon. EnvoyAI is the spinout formed by a 2017 TeraRecon acquisition of McCoy Medical Technologies. TeraRecon�s longstanding partnership with Insignia is further strengthened with the synergies between EnvoyAI�s platform and TeraRecon�s latest advanced visualisation offerings. The integrations with EnvoyAI and TeraRecon allow hospitals to customize their AI portfolio based on algorithms they can test and consume from within their Insignia PACS, including the utilisation of each hospital�s own internally developed algorithms. Jon Hall, Chief Technology Officer, Insignia Medical Systems shared, �Integrating to the EnvoyAI platform allows Insignia to more quickly and broadly execute on our goal of providing the most advanced functionality on the market to our end users. The integration provides instant access to premium AI directly as part of a cohesive end-user experience - expanding how we add value for our customers within a single, powerful interface.� The EnvoyAI platform readies the Insignia InSight PACS for the launch of any AI application � starting with the AI content already available on the EnvoyAI Exchange. With recent growth, the EnvoyAI Exchange now offers a total of 53 products from 22 partners, of which 10 have already achieved US FDA-clearance. The partnership creates added potential for future workflow integrations to TeraRecon�s iNtuition advanced visualisation solution already promoted by Insignia, as well as TeraRecon�s new NorthStar AI-results viewer for advanced physician interactions. Maria Proud-Levitas, Regional Sales Manager for TeraRecon (UK) said, �Working closely with Insignia for over 5 years has created a very clean and powerful offering for our customers. Building on that trust, we now look forward to delivering tools that take UK healthcare boldly into the future.� Steven Rothenberg, MD and Chief Medical Officer of EnvoyAI stated, �The Insignia PACS integration makes the widespread use of AI an immediate reality for clinicians across the UK; allowing for the most rigorous data security protocols with on-premise installations. EnvoyAI is keen on bringing AI to clinicians i

press report 5 times the posts disapear on here. Anyway I have 4p target up to OGA licence news and 8p on farm out. 20p for the drill Im not going anywhere

http://uk.businessinsider.com/japan-moving-back-to-coal-2018-5 Japan is moving back to coal. The move would make 26% of the country's electricity come from coal by 2030. A 2011 meltdown at the Fukushima Daiichi Nuclear Power Station partly spurred the policy change. The coal industry may actually be revived for the moment, as China and India are also using more coal. one major economy is breaking the trend. Japan, in a move that few could have foreseen, has opened at least eight brand new coal-burning power plants in the last two years and has plans for at least 36 more in the next ten years. This ambitious return to coal far outstrips any other developed nation, and it�s only speeding up. Last month the Japanese government made major advancements to officially adopt a national energy plan that would see 26 percent of the country�s total electricity come from coal in 2030, directly contradicting a previous directive to cut back coal usage to just 10 percent of total electricity.

All sounds positive from RNSs. http://uk.businessinsider.com/japan-moving-back-to-coal-2018-5 Japan is moving back to coal. The move would make 26% of the country's electricity come from coal by 2030. A 2011 meltdown at the Fukushima Daiichi Nuclear Power Station partly spurred the policy change. The coal industry may actually be revived for the moment, as China and India are also using more coal. Japan, in a move that few could have foreseen, has opened at least eight brand new coal-burning power plants in the last two years and has plans for at least 36 more in the next ten years.

before Licence announcement - no advice intended - this is my personal goal. 3-4p pre licence OGA 30th round announcement. This didnt even dip on the last private fundraise with Michael Spencer. They get the licence, then its clear they want to drill in 2019, So 6-10p pre drill run up. Do your own research, no advice intended. Just my thoughts.

http://www.heraldscotland.com/business_hq/16195587.French_oil_giant_sees_a_bright_future_in_the_UK_North_Sea/ CLUFF is in this article

is a low lower than what it sort of says due to sticky holders. So much less shares free to circulate so mechanics dictate as volume grows this will simply keep moving up.

and there is always 1 share which 10 or 20 bags - this may well be it.